Last $0.09 USD
Change Today -0.01 / -10.53%
Volume 10.0K
As of 8:10 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

admedus ltd (AMEUF) Snapshot

Open
$0.09
Previous Close
$0.10
Day High
$0.09
Day Low
$0.09
52 Week High
03/7/14 - $0.19
52 Week Low
02/24/15 - $0.08
Market Cap
122.6M
Average Volume 10 Days
5.3K
EPS TTM
--
Shares Outstanding
1.4B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADMEDUS LTD (AMEUF)

Related News

No related news articles were found.

admedus ltd (AMEUF) Related Businessweek News

No Related Businessweek News Found

admedus ltd (AMEUF) Details

Admedus Limited, a diversified healthcare company, focuses on developing and commercializing next generation technologies. The company is involved in the process of commercializing its tissue engineering technology for regenerative medicine. It provides CardioCel, a cardiovascular scaffold for the repair and correction of congenital heart deformities, and repair of damaged tissue, including defective heart valves. The company is also developing the next generation vaccines that target diseases, such as herpes and human papillomavirus. In addition, it distributes disposable medical products and medical devices, as well as is involved in the bioimplants and DNA vaccines operations. The company was formerly known as Allied Healthcare Group Limited and changed its name to Admedus Limited in November 2013. Admedus Limited is based in Perth, Australia.

admedus ltd (AMEUF) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$350.9K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$191.5K
Chief Operating Officer
Total Annual Compensation: A$315.3K
Executive Director
Total Annual Compensation: --
Executive
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

admedus ltd (AMEUF) Key Developments

Admedus Limited Announces Unaudited Consolidated Earnings Results for the Half Year Ended December 31, 2014

Admedus Limited announced unaudited consolidated earnings results for the half year ended December 31, 2014. For the period, the company's revenue from continuing operations was AUD 4.8 million compared with AUD 4.1 million a year ago. Loss before income tax from continuing operations was AUD 11.5 million compared with AUD 1.6 million a year ago. Loss after income tax for the period was AUD 11.4 million compared with AUD 1.5 million a year ago. Loss is attributable to equity holders of the company was AUD 10.7 million or 0.741 AUD cents per basic share compared with AUD 0.75 million or 0.069 AUD cents per basic share a year ago. Net cash outflow from operating activities was AUD 9.6 million compared with AUD 3.7 million a year ago. Payments for property, plant & equipment was AUD 0.29 million compared with AUD 0.13 million a year ago. Payments for intangible assets was AUD 0.05 million compared with AUD 0.04 million a year ago.

Admedus Limited Presents at Leerink's Global Healthcare Conference, Feb-11-2015 08:00 AM

Admedus Limited Presents at Leerink's Global Healthcare Conference, Feb-11-2015 08:00 AM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Lee Rodne, Chief Executive Officer, Managing Director and Executive Director.

Admedus Limited Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 08:00 AM

Admedus Limited Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 08:00 AM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: Lee Rodne, Chief Executive Officer, Managing Director and Executive Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMEUF:US $0.09 USD -0.01

AMEUF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMEUF.
View Industry Companies
 

Industry Analysis

AMEUF

Industry Average

Valuation AMEUF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.7x
Price/Book 5.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADMEDUS LTD, please visit www.admedus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.